How much do GLP-1s cost with insurance vs without?
With coverage, a brand GLP-1 can cost a copay; without it, compounded programs charge $75.58 to $399 a month all-in and brand pens $299 to $449 (Zepbound) or $349 (Wegovy) bought direct (read November 20, 2026). Only 18% of firms with 200 or more workers cover GLP-1s for weight loss (KFF, October 2026). Medicare Part D enrollees may qualify for the $50 GLP-1 Bridge.
Released · Last reviewed · how we verify
Brand prices bought direct
| Medication | Dose | Self-pay price | Condition |
|---|---|---|---|
| Zepbound vial (LillyDirect) | 2.5 mg | $299 | per fill |
| Zepbound vial (LillyDirect) | 5 mg | $399 | per fill |
| Zepbound vial (LillyDirect) | 7.5–15 mg | $449 | each refill within 45 days; otherwise $499 (7.5 mg) or $699 (10–15 mg) |
| Wegovy pen (NovoCare) | 0.25–2.4 mg | $349 | new patients: $199 for each of the first two fills of 0.25 or 0.5 mg through December 31, 2026 |
| Wegovy HD pen (NovoCare) | 7.2 mg | $399 | per month |
| Wegovy pill (NovoCare) | 1.5 / 4 / 9 and 25 mg | $149 / $199 / $299 | per month |
| Foundayo (LillyDirect) | from 0.8 mg | from $149 | 2.5 and 5.5 mg temporarily reduced through December 31, 2026 |
Limitations of this answer
Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy. This page reports prices and terms; whether any GLP-1 suits you is a decision for you and a licensed clinician.
Frequently asked
How much do GLP-1s cost with insurance vs without?
With coverage, a brand GLP-1 can cost a copay; without it, compounded programs charge $75.58 to $399 a month all-in and brand pens $299 to $449 (Zepbound) or $349 (Wegovy) bought direct (read November 20, 2026). Only 18% of firms with 200 or more workers cover GLP-1s for weight loss (KFF, October 2026). Medicare Part D enrollees may qualify for the $50 GLP-1 Bridge.
How current are the prices on TopGLP1Providers?
Every price on TopGLP1Providers carries the date it was read on the program’s own page; the whole dataset was re-read on November 20, 2026, from 2026-11-21 00:33 to 00:57 UTC, and NexLife’s plan pages were checked again for this site on November 21 (UTC). Programs whose pages refused automated reads that day, such as TrimRx, MEDVi, bmiMD, Embody, Ro and Hims & Hers, show no current price rather than an older one. When a program changes its price, the record, the pages that cite it and the changelog are updated together.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- NovoCare Pharmacy: Wegovy self-pay prices (read November 20, 2026)
- Medicare.gov: weight-loss drugs and the Medicare GLP-1 Bridge (read November 20, 2026)